Reference documents in Prequalification of vaccines

Kunming, China, 14-18 March 2016







General documents

Vaccines against	TRS Number	Link	Comments
PQ procedure	TRS 978, Annex 6 (2012)	http://www.who.int/entity/immuni zation_standards/vaccine_quality/T RS_978_61st_report_Annex_6_PQ vaccine_procedure.pdf	
GCP	TRS 850 (1995)	http://apps.who.int/prequal/info_g eneral/documents/TRS850/WHO_T RS_850-Annex3.pdf	
Non-clinical evaluation of vaccines	TRS 927 (2005)	http://who.int/biologicals/vaccines/ nonclinial_evaluation_of_vaccines/ en/	
Clinical evaluation of vaccines	TRS 924 (2004)	http://who.int/entity/biologicals/vaccines/clinical_evaluation/en/index.htm	
Important clinical considerations		http://www.who.int/immunization_standards/vaccine_quality/pq_vaccine_evaluation/en/	Not a TRS but summarizes key requirements



Vaccine against	TRS Number	Link	Comments
Tuberculosis	TRS 979 (2013)	http://www.who.int/biologica ls/areas/vaccines/TRS_979_A nnex_3.pdf?ua=1	No correlate of protection. Efficacy study required with BCG as comparator
Cholera			No correlate of protection. Efficacy study is required with PQ vaccine as comparator
DT based Combined Vaccines	TRS 980 (2014)	http://www.who.int/biologica ls/vaccines/Combined_Vaccin es_TRS_980_Annex_6.pdf?ua =1	Correlate of protections except for pertussis, the magnitude of response is compared between the responses to test and control (non-inf – 95% upper CI GMC or GMT ratio usually less 1.5 or 2.0 or as agreed with NRA)
Dengue	TRS 979 (2013)	http://www.who.int/biologica ls/areas/vaccines/TRS_979_A nnex_2.pdf?ua=1	Efficacy study required





Vaccines against	TRS Number	Link	Comments
Hepatitis A		http://www.who.int/wer/201 2/wer8728_29.pdf?ua=1 (WER, No. 28-29, 2012, 87, 261–276)	Correlates of protection proposed but a positive (qualitative) test for total anti-HAV antibodies is considered to signify immunity to hepatitis A
Hepatitis B		http://www.who.int/wer/200 9/wer8440.pdf?ua=1 (WER, No. 40, 2009, 84, 405–420)	Correlate of protection
HPV	TRS 962 (2011) An update is awaited	http://www.who.int/biologica ls/vaccines/hpv/Annex_1_WH O_TRS_962-2.pdf?ua=1	Based on rates of CIN2/3 and AIS associated with vaccine HPV types after three vaccine doses on schedule.
Influenza		http://www.who.int/wer/201 2/wer8747.pdf?ua=1	Correlate of protection





Vaccines against	TRS Number	Link	Comments
Japanese Encephalitis Vaccine	TRS 963 (2011)	http://www.who.int/biologica ls/vaccines/japanese_enceph alitis/en/	Correlates of protection exist
	TRS 980 (2014)	http://www.who.int/biologica ls/vaccines/JE- Recommendations_TRS_980_ Annex_7.pdf?ua=1	
Measles	TRS 840 (1994)	http://www.who.int/biologica ls/publications/trs/areas/vacc ines/mmr/WHO_TRS_840_A3 .pdf?ua=1	Correlates of protection exist
Meningococcal Vaccine	TRS 962 (2011) (also 924, 926, 963)	http://www.who.int/biologica ls/vaccines/Annex_2_WHO_T RS_962.pdf?ua=1	Correlates of protection exist
Pneumococcal Vaccine	TRS 977 (2013)	http://www.who.int/biologica ls/vaccines/TRS_977_Annex_ 3.pdf?ua=1	Correlates of protection exist







Vaccine	TRS Number	Link	Comments
Poliomyelitis	TRS 926 (2004) TRS 993 (2015)	http://www.who.int/biologicals/publications/trs/areas/vaccines/polio/Annex%202%20(65-89)TRS926Polio2003.pdf?ua=1 http://www.who.int/biologicals/vaccines/Annex3_IPV_Recommendations_eng.pdf?ua=1	Correlates of protection exist
Rota virus	TRS 941 (2007)	http://www.who.int/biologicals/publications/trs/areas/vaccines/rotavirus/Annex%203%20rotavirus%20vaccines.pdf?ua=1	Efficacy study needed
Typhoid	TRS 987 (2014)	http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex3.pdf?ua=1	In age group 2 years and older, group the pre- licensure assessment of the likely protective efficacy of conjugated Vi vaccines could be based on appropriate studies of comparative immunogenicity using validated assays (supported by challenge studies) In less than 2 years, efficacy study needed (NRA could depending on burden of disease decide on appropriate immunogenicity study followed by post approval effectiveness)
Yellow Fever	TRS 978 (2013)	http://www.who.int/biologicals/ar eas/vaccines/TRS_978_Annex_5.p df?ua=1	Efficacy study not needed

Notice

It is crucial to be very conversant with the guidelines related to each vaccine and ask question if necessary





